Lupus Nephritis Market Size and Share Analysis 2034 – Clinical Trials, Patient Pool Forcasting, Medication, Prevalence, Companies by DelveInsight

Lupus Nephritis Market

Lupus nephritis Market Summary

The 2024 Lupus nephritis market size was ~USD 1.8 billion, dominated by BENLYSTA and LUPKYNIS, the only FDA-approved therapies. A strong pipeline— including Novartis’s ianalumab, FABHALTA, and CAR-T therapy, plus agents like GAZYVA and SAPHNELO— is expected to expand treatment options and drive market growth by 2034. Lupus nephritis (LN) is a severe complication of systemic lupus erythematosus (SLE), affecting 40–60% of patients, with 10–30% progressing to end-stage renal disease (ESRD) despite therapy. While incidence peaked around 2020 and has since declined, prevalence continues to rise due to improved survival, reflecting a growing but stabilizing disease burden. Class IV Lupus nephritis remains the most common and severe subtype, marked by poor remission and relapse risk, while Classes I–II are milder and Class V presents challenges with proteinuria and overlap forms. In 2024, diagnosed LN cases in the 7MM reached ~385,000, projected to increase by 2034, with Spain reporting the highest EU4+UK burden.

DelveInsight’s “Lupus Nephritis Market Insights, Epidemiology, and Market Forecast – 2034” provides a comprehensive analysis of lupus nephritis across the US, EU5, and Japan. The report includes historical and projected epidemiology, treatment practices, emerging therapies, market size, and therapy share from 2020-2034. It also examines treatment algorithms, key drivers, barriers, unmet needs, and future opportunities in the lupus nephritis market.

Request for a Free Sample Report @ Lupus Nephritis Market Forecast

Some facts of the Lupus Nephritis Market Report are:

• According to DelveInsight, Lupus Nephritis market size is expected to grow at a decent CAGR by 2034.
• The total lupus nephritis market size in the 7MM is approximately USD 1,120 million in 2022 and is projected to increase during the forecast period (2023–2034).
• In the total Lupus Nephritis market size in the 7MM, the United States accounted for the highest market share that is more than 80% in 2023, followed by Japan and the Spain.
• Leading Lupus Nephritis companies working in the market are Aurinia Pharmaceuticals, Roche, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Otsuka Pharmaceutical, MorphoSys, Vertice Pharma, Pharmaceutical Associates Inc., Sun Pharmaceutical, Abbott, Johnson & Johnson Private Limited, Bayer, Sanofi, Sumitomo Corporation, LEO Pharma A/S, Cipla, and Nimble Pharmaceuticals, and others.
• Key Lupus Nephritis Therapies expected to launch in the market are BENLYSTA (belimumab), LUPKYNIS (voclosporin), Ianalumab (VAY736), SAPHNELO (anifrolumab), GAZYVA/GAZYVARO (obinutuzumab), Anifrolumab and others.
• In June 2025, Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived off-the-shelf cellular immunotherapies to patients, announced new and updated clinical data from the first five patients dosed with FT819 for the treatment of moderate-to-severe systemic lupus erythematosus (SLE) at the European Alliance of Associations for Rheumatology (EULAR) 2025 Congress in Barcelona, Spain.
• In March 2025, Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application (sBLA) for Gazyva®/Gazyvaro® (obinutuzumab) for the treatment of lupus nephritis. This acceptance is supported by positive findings from the Phase III REGENCY trial, which demonstrated enhanced complete renal response (CRR) when Gazyva/Gazyvaro was added to standard therapy, compared to standard treatment alone. The FDA is expected to deliver a decision on the application by October 2025.
• In February 2025, A new phase 3, placebo-controlled study showed that adding the anti-CD20 monoclonal antibody obinutuzumab (Gazyva) to standard treatment for lupus nephritis offers greater effectiveness than standard therapy alone. At 76 weeks, 46.4% of patients receiving obinutuzumab achieved a complete renal response, compared to 33.1% in the standard therapy group. Complete renal response was defined by a urinary protein-to-creatinine ratio (UPCR) below 0.5, an estimated glomerular filtration rate (eGFR) of at least 85% of baseline, and the absence of intercurrent events such as rescue therapy, treatment failure, or early study discontinuation.
• In February 2025, Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company focused on developing innovative small molecule therapies for immune-mediated diseases, announced its participation in a virtual Key Opinion Leader (KOL) event hosted by William Blair. The company will discuss the clinical development of zetomipzomib for autoimmune hepatitis (AIH) and share a safety update from the PALIZADE Phase 2b trial in patients with active lupus nephritis.
• In February 2025, the FDA cleared Allogene Therapeutics’ investigational new drug (IND) application for ALLO-329, an allogenic CAR-T cell therapy. Researchers are set to begin the Phase 1 RESOLUTION trial in mid-2025 for autoimmune diseases, including systemic lupus erythematosus (SLE), lupus nephritis (LN), idiopathic inflammatory myopathies, and systemic sclerosis.
• In November 2024, Adicet Bio announced that the first LN patient had been dosed in the Phase I clinical trial evaluating ADI-001 in autoimmune diseases.
• In November 2024, Kyverna Therapeutics announced that it would present updated clinical data from LN patients treated with KYV-101 in ongoing Kyverna-sponsored KYSA-1 and KYSA-3 Phase I/II studies and named patient treatments.
• In June 2024, Nkarta announced the initiation of Ntrust-I, a multi-center clinical trial of NKX019 in lupus nephritis, with the first patient in screening. The company also announced the clearance by the U.S. Food and Drug Administration (FDA) of its second Investigational New Drug (IND) application for NKX019 in autoimmune disease.
• In June 2024, Adicet Bio announced that the US Food and Drug Administration (FDA) had granted Fast Track Designation to ADI-001 for the potential treatment of relapsed/refractory class III or class IV lupus nephritis.
• In April 2024, Caribou Biosciences announced that it had received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) for CB-010, an allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout (KO), for the treatment of lupus nephritis (LN) and extrarenal lupus (ERL). The Phase 1, multicenter, open label GALLOP clinical trial of CB-010 in patients with LN and ERL is expected to initiate by year-end 2024.
• In March 2024, Artiva Therapeutics is looking to dose the first patient in a Phase I/II trial assessing its cell therapy AlloNK in lupus nephritis (LN).

Lupus Nephritis Overview

Lupus nephritis (LN) is a severe complication of systemic lupus erythematosus (SLE), an autoimmune disease that affects multiple organs. It occurs when the immune system attacks the kidneys, causing inflammation and damage to the glomeruli, leading to impaired kidney function. LN is a major cause of morbidity in lupus patients and can progress to chronic kidney disease (CKD) or end-stage renal disease (ESRD) if untreated.

Symptoms of lupus nephritis vary but commonly include proteinuria, hematuria, edema (especially in the legs and face), hypertension, and declining kidney function. Diagnosis is confirmed through kidney biopsy, which helps classify LN into different histological classes based on severity. Blood tests, urine analysis, and estimated glomerular filtration rate (eGFR) are also essential for disease monitoring.

Lupus nephritis Treatment focuses on reducing inflammation, preserving kidney function, and preventing flare-ups. Immunosuppressive therapy with corticosteroids, mycophenolate mofetil (MMF), or cyclophosphamide is the standard approach. In refractory cases, biologics like belimumab or rituximab may be used. Blood pressure control with ACE inhibitors or angiotensin receptor blockers (ARBs) is crucial in managing proteinuria.

Early Lupus nephritis diagnosis and aggressive treatment are essential to improving prognosis and preventing kidney failure in lupus nephritis patients.

Learn more about Lupus Nephritis treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Lupus Nephritis Treatment Market – https://www.delveinsight.com/sample-request/lupus-nephritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Lupus Nephritis Market

The Lupus Nephritis market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Lupus Nephritis market trends by analyzing the impact of current Lupus Nephritis therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Lupus Nephritis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Lupus Nephritis market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Lupus Nephritis market in 7MM is expected to witness a major change in the study period 2020-2034.

Lupus Nephritis Epidemiology

The epidemiology of Lupus Nephritis (LN) in the 7MM (US, EU4, UK, and Japan) covers data from 2020–2034, segmented by diagnosed prevalence, age, class, and treated cases. In 2024, the US recorded about 218,000 diagnosed prevalent cases, representing ~60% of the total 7MM population. The EU4 and UK together accounted for ~130,000 cases, with Spain having the highest and France the lowest numbers. In the US, 7% of cases were in individuals

Lupus Nephritis Epidemiology Segmented

• Total Diagnosed Prevalent Cases
• Age-specific Diagnosed Prevalent Cases
• Diagnosed Prevalent Cases by Class
• Total Treated Cases of Lupus Nephritis

Explore more about Lupus Nephritis Epidemiology @ Lupus Nephritis Patient Pool Forecasting and Market Dynamics

Lupus Nephritis Pipeline Development Activities and Drugs Uptake

GAZYVA/GAZYVARO (obinutuzumab) – Roche Obinutuzumab is a Type II CD20-targeting monoclonal antibody with stronger cytotoxic activity than traditional CD20 antibodies, driving B-cell lysis via immune effector mechanisms. Marketed as GAZYVARO in Europe, it is under evaluation in two Phase III trials. In March 2025, the FDA accepted a supplemental BLA for lupus nephritis, with a decision expected by October 2025; EMA review is also underway using Phase III REGENCY data.

Ianalumab (VAY736) – Novartis Ianalumab is a fully human, subcutaneous BAFF-R antibody designed for ADCC-mediated B-cell depletion. It is in Phase III development for autoimmune conditions, including lupus nephritis, with a regulatory submission targeted for 2028.

Lupus Nephritis Pipeline Development Activities

The Lupus Nephritis report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Lupus Nephritis key players involved in developing targeted therapeutics.

Request for a sample report to understand more about the Lupus Nephritis pipeline development activities @ Lupus Nephritis Drugs Market – https://www.delveinsight.com/sample-request/lupus-nephritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Lupus Nephritis Therapeutics Assessment

Major key companies are working proactively in the Lupus Nephritis Therapeutics market to develop novel therapies which will drive the Lupus Nephritis treatment markets in the upcoming years are Aurinia Pharmaceuticals (NASDAQ: AUPH), Roche (SWX: ROG), AstraZeneca (LSE: AZN), Boehringer Ingelheim, GlaxoSmithKline (LSE: GSK), Novartis (SWX: NOVN), Otsuka Pharmaceutical (TYO: 4578), MorphoSys (ETR: MOR), Vertice Pharma (Privately Held), Pharmaceutical Associates Inc. (Privately Held), Sun Pharmaceutical (NSE: SUNPHARMA), Abbott (NYSE: ABT), Johnson & Johnson Private Limited (NYSE: JNJ), Bayer (ETR: BAYN), Sanofi (EPA: SAN), Sumitomo Corporation (TYO: 8053), LEO Pharma A/S (Privately Held), Cipla (NSE: CIPLA), and Nimble Pharmaceuticals, and others.

Learn more about the emerging Lupus Nephritis therapies & key companies @ Lupus Nephritis Clinical Trials and Advancements – https://www.delveinsight.com/sample-request/lupus-nephritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Lupus Nephritis Report Key Insights

1. Lupus Nephritis Patient Population

2. Lupus Nephritis Market Size and Trends

3. Key Cross Competition in the Lupus Nephritis Market

4. Lupus Nephritis Market Dynamics (Key Drivers and Barriers)

5. Lupus Nephritis Market Opportunities

6. Lupus Nephritis Therapeutic Approaches

7. Lupus Nephritis Pipeline Analysis

8. Lupus Nephritis Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Lupus Nephritis Market

Table of Contents

1. Key Insights

2. Executive Summary

3. Lupus Nephritis Competitive Intelligence Analysis

4. Lupus Nephritis Market Overview at a Glance

5. Lupus Nephritis Disease Background and Overview

6. Lupus Nephritis Patient Journey

7. Lupus Nephritis Epidemiology and Patient Population

8. Lupus Nephritis Treatment Algorithm, Current Treatment, and Medical Practices

9. Lupus Nephritis Unmet Needs

10. Key Endpoints of Lupus Nephritis Treatment

11. Lupus Nephritis Marketed Products

12. Lupus Nephritis Emerging Therapies

13. Lupus Nephritis Seven Major Market Analysis

14. Attribute Analysis

15. Lupus Nephritis Market Outlook (7 major markets)

16. Lupus Nephritis Access and Reimbursement Overview

17. KOL Views on the Lupus Nephritis Market

18. Lupus Nephritis Market Drivers

19. Lupus Nephritis Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services